PD-L1

PD-L1—short for “programmed death ligand 1”—is a protein produced by cancer cells that inactivate T-cells, which play a major role in immune response. A promising group of drugs called PD-L1 inhibitors are being developed for cancer patients. They work by blocking PD-L1, thereby boosting the body’s immune response against cancer cells.